首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Anti‐angiogenic therapy: Adapting strategies to overcome resistant tumors
Authors:Dianne C Mitchell  Brad A Bryan PhD
Institution:1. Acceleron Pharmaceuticals, Cambridge, Massachusetts;2. Ghosh Science and Technology Center, Department of Biology, Worcester State College, Worcester, Massachusetts
Abstract:Healthy cells, as well as benign and malignant tumors, depend upon the body's blood supply to bring in oxygen and nutrients and carry away waste products. Using this property against tumors, anti‐angiogenic therapy targets the tumor vasculature with the aim of starving the tumor, and has demonstrated exceptional clinical efficacy against a number of tumors. This review discusses the current state of knowledge regarding anti‐angiogenic therapies presently available to patients, and garners from both preclinical and clinical literature the benefits and side effects associated with anti‐angiogenic therapies, the unfortunate mechanisms of acquired resistance to these novel therapeutics, and highlights promising next generation anti‐angiogenics that may overcome the limitations encountered with first generation therapies. J. Cell. Biochem. 111: 543–553, 2010. © 2010 Wiley‐Liss, Inc.
Keywords:vascular endothelial growth factor  Avastin  angiogenesis
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号